Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial

on behalf of the VALID Study Organization, Piero Ruggenenti, Matias Trillini, Drazenka P. Barlovic, Monica Cortinovis, Antonio Pisani, Aneliya Parvanova, Ilian P. Iliev, Barbara Ruggiero, Stefano Rota, Maria C. Aparicio, Annalisa Perna, Francesco Peraro, Olimpia Diadei, Flavio Gaspari, Fabiola Carrara, Nadia Stucchi, Davide Martinetti, Andrej Janez, Nadan GregoricEleonora Riccio, Antonio C. Bossi, Roberto Trevisan, Paolo Manunta, Giovanni Battaglia, Salvatore David, Filippo Aucella, Antonio Belviso, Andrea Satta, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: To evaluate whether angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) combination therapy is more nephroprotective than ACE inhibitor or ARB monotherapy in people with type 2 diabetes and overt nephropathy. Materials and methods: In this prospective, randomized, open, blind-endpoint phase III trial sponsored by the Italian Drug Agency, 103 consenting patients with type 2 diabetes, aged >40 years, with serum creatinine levels 159 to 309 μmol/L, spot morning urinary albumin–creatinine ratio > 1000 mg/g (or > 500 mg/g in those on ACE inhibitor or ARB therapy at inclusion) were stratified by centre and randomized to 4.5-year treatment with valsartan 320 mg/d (n = 36), benazepril 20 mg/d (n = 34) or halved doses of both medications (n = 33). The primary endpoint was end-stage renal disease (ESRD). Modified intention-to-treat analyses were performed. Results: Recruitment took place between June 2007 and February 2013 at 10 centres in Italy and one in Slovenia. A total of 77 participants completed the study and 26 were prematurely withdrawn. During a median (interquartile range) of 41 (18–54) months, 12 participants on benazepril (35.3%) and nine on combination therapy (27.3%) progressed to ESRD, versus five on valsartan (13.9%). Differences between benazepril (hazard ratio [HR] 3.59, 95% confidence interval [CI] 1.25–10.30; P = 0.018) or combination therapy (HR 3.28, 95% CI 1.07–10.0; P = 0.038) and valsartan were significant, even after adjustment for age, gender and baseline serum creatinine, systolic blood pressure and 24-hour proteinuria (HR 5.16, 95% CI 1.50–17.75, P = 0.009 and HR 4.75, 95% CI 1.01–22.39, P = 0.049, respectively). Adverse events were distributed similarly among the groups. Conclusions: In people with type 2 diabetes with nephropathy, valsartan (320 mg/d) safely postponed ESRD more effectively than benazepril (20 mg/d) or than halved doses of both medications.
Original languageItalian
Pages (from-to)1177-1190
Number of pages14
JournalDiabetes, Obesity and Metabolism
Volume21
Issue number5
DOIs
Publication statusPublished - May 1 2019

Cite this